- Home
- CRDF
as 04-18-2025 1:34pm EST
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 195.6M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $5.64 | Next Earning Date: | 05-01-2025 |
| Revenue: | $683,000 | Revenue Growth: | 39.96% |
| Revenue Growth (this year): | -57.33% | Revenue Growth (next year): | -65.00% |
Latest Cardiff Oncology Inc. News
CRDF Breaking Stock News: Dive into CRDF Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 days ago
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
Simply Wall St.
2 months ago
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations
GlobeNewswire
2 months ago
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
GuruFocus.com
2 months ago
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: What To Look For
GlobeNewswire
2 months ago
Cardiff Oncology to Present at Upcoming Investor Conferences
GlobeNewswire
2 months ago
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Simply Wall St.
2 months ago
Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m
Compare CRDF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRDF Cardiff Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.